원진바이오테크놀로지
Suwon, KR · 1 known investors
Find your way into 원진바이오테크놀로지
Onegene develops multi-modality drugs using enzyme-mediated protein-protein conjugation technology to create multispecific therapeutics for complex diseases. Its pipeline includes a tetra-specific treatment for non-alcoholic steatohepatitis (NASH) and a tri-specific approach for T-cell-based immune activation in oncology.
Founders & leadership
SP
SungJin ParkinCEOHe began leading Onegene Group and ONEGENE Biotechnology in 2016, following a research career in the United States. He worked as a postdoctoral fellow and postdoctoral associate at Northwestern University, including the Feinberg School of Medicine, from 2010 to 2016, after serving as a research assistant at the University of North Carolina at Chapel Hill from 2005 to 2010.
Investors · 1
Competitors · 3
by search overlap
Origene3 shared keywordsOriGene develops and supplies genomic and proteomic research tools, including proteins and antibodies built on its proprietary cDNA clone collections, for life science researchers. The company offers a broad catalog of research products used in scientific discovery and diagnostics development.
Thumbnail for Seragon Pharmaceuticals3 shared keywordsGenentech is a biotechnology company that develops and manufactures breakthrough medicines in the United States, backed by a $50 billion commitment to U.S. manufacturing and scientific innovation.
One Biosciences3 shared keywordsOneBio Sciences provides clinical-grade single-cell RNA sequencing analysis of tumor samples to support cancer diagnostics and drug development. The platform delivers tumor intelligence reports with functional signatures for precision oncology within two weeks.
Companies competing with 원진바이오테크놀로지 for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does 원진바이오테크놀로지 do?
- Onegene develops multi-modality drugs using enzyme-mediated protein-protein conjugation technology to create multispecific therapeutics for complex diseases. Its pipeline includes a tetra-specific treatment for non-alcoholic steatohepatitis (NASH) and a tri-specific approach for T-cell-based immune activation in oncology.
- Who are 원진바이오테크놀로지's investors?
- 원진바이오테크놀로지's investors include Solidus Investment.
- Where is 원진바이오테크놀로지 headquartered?
- 원진바이오테크놀로지 is headquartered in Suwon, KR.